Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539608 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL16727813 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL15540189 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL817926 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL10261997 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL16727811 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL17212370 | 1.00 | TSHR (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL24419237 | 0.89 | ALDH1A1 (0.38) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL15999633 | 0.89 | TSHR (0.39) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL19478755 | 0.88 | ALDH1A1 (0.41) | TSHRALDH1A1MAPK1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464162-A1 | COMPOSITIONS FOR EXTENDING THE SHELF LIFE OF A FOOD PRODUCT, METHOD FOR PRODUCING THE COMPOSITIONS, USES THEREOF | Agree NET S.r.l. (IT) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024046698-A1 | EPOXIDE-ALCOHOL-BASED MULTI-COMPONENT RESIN SYSTEM | HILTI AKTIENGESELLSCHAFT (LI) | 2024-03-07 | — | — | WO | disclosed |
| EP-4332143-A1 | MULTICOMPONENT EPOXY-ALCOHOL-BASED RESIN SYSTEM | Hilti Aktiengesellschaft (LI) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022096148-A1 | OLIGOMERIC EPOXY PRE-POLYMERS COMPRISING ISOSORBIDE UNITS | ROQUETTE FRERES (FR) | 2022-05-12 | — | — | WO | disclosed |
| US-10913817-B2 | Use of a composition of low-viscosity bis-anhydrohexitol ethers as a reactive diluent for crosslinkable resin, adhesive, coating and matrix compositions for composites | ROQUETTE FRERES (FR) | 2021-02-09 | — | — | US | disclosed |
| US-20200262955-A1 | Isosorbide derivatives as reactive additives in reactive resins and chemical dowels | HILTI AKTIENGESELLSCHAFT (LI) | 2020-08-20 | — | — | US | disclosed |
| US-20200123308-A1 | USE OF A COMPOSITION OF LOW-VISCOSITY BIS-ANHYDROHEXITOL ETHERS AS A REACTIVE DILUENT FOR CROSSLINKABLE RESIN, ADHESIVE, COATING AND MATRIX COMPOSITIONS FOR COMPOSITES | ROQUETTE FRERES (FR) | 2020-04-23 | — | — | US | disclosed |
| EP-3489205-A1 | ISOSORBIDE DERIVATIVES AS REACTIVE ADDITIVES IN REACTIVE RESINS AND CHEMICAL DOWELS | HILTI Aktiengesellschaft (LI) | 2019-05-29 | — | — | EP | disclosed |
| US-9156851-B2 | Photocurable dianhydro-hexane-hexol derivative, manufacturing method thereof, and photocurable composition including same | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2015-10-13 | — | — | US | disclosed |
| US-9156851-B2 | Photocurable dianhydro-hexane-hexol derivative, manufacturing method thereof, and photocurable composition including same | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140249285-A1 | RENEWABLE BIO-BASED (METH) ACRYLATED MONOMERS AS VINYL ESTER CROSS-LINKERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140073716-A1 | PHOTOCURABLE DIANHYDRO-HEXANE-HEXOL DERIVATIVE, MANUFACTURING METHOD THEREOF, AND PHOTOCURABLE COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2014-03-13 | — | — | US | disclosed |
| US-20140073716-A1 | PHOTOCURABLE DIANHYDRO-HEXANE-HEXOL DERIVATIVE, MANUFACTURING METHOD THEREOF, AND PHOTOCURABLE COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2014-03-13 | — | — | US | disclosed |
| WO-2013066461-A2 | RENEWABLE BIO-BASED (METH) ACRYLATED MONOMERS AS VINYL ESTER CROSS-LINKERS | PALMESE GIUSEPPE R (US) | 2013-05-10 | — | — | WO | disclosed |
| US-7754823-B2 | Vegetable based dioxanone derivatives, synthesis and uses thereof | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754823-B2 | Vegetable based dioxanone derivatives, synthesis and uses thereof | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073716-A1 | PHOTOCURABLE DIANHYDRO-HEXANE-HEXOL DERIVATIVE, MANUFACTURING METHOD THEREOF, AND PHOTOCURABLE COMPOSITION INCLUDING SAME | HDHD5, DOHH, HPD | TSHR 4815/4885ALDH1A1 410/4885MAPK1 2925/4885 |
| US-20140249285-A1 | RENEWABLE BIO-BASED (METH) ACRYLATED MONOMERS AS VINYL ESTER CROSS-LINKERS | MACF1, ADH7, CD38 | TSHR 3768/4885ALDH1A1 199/4885MAPK1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.